Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a Nov. 6 release from the FDA. Executives from both companies stood alongside Trump at a press conference today highlighting their new pricing deals with the White House.

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive order to address US drug pricing disparities. Novo Nordisk's semaglutide agents and Eli Lilly's tirzepatide will be significantly cheaper through TrumpRx, a new government platform launching in 2026.

Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines.

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

The Michigan Supreme Court heard oral arguments Wednesday in the state attorney general’s case against insulin-maker Eli Lilly and Company.

Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) and Novo Nordisk (NVO) will lower GLP-1 prices as a result of newly made agreements with the Trump administration.

Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients,